PSC Investments Acquires Sterile Injectable Fill/Finish Facility

August 25, 2014
BioPharm International Editors

PSC Investments announces the acquisition of a high potency, sterile fill/finish pharmaceutical manufacturing facility.

PSC Investments, a subsidiary of California-based PSC Biotech Corporation, has announced the acquisition of a high potency, sterile injectable facility from the Morgridge Institute for Research (MIR), a private research institute affiliated with the University of Wisconsin-Madison. The contract manufacturing operation will be named BioTechnique and will be a newly formed subsidiary of PSC Biotech.

The 37,000-sq-ft sterile injectable fill/finish facility, located in Madison’s University Research Park, was constructed in 2008 by Mentor Biologics, Inc. and later conveyed to MIR.

The recent acquisition will allow BioTechnique to provide specialized filling services for cytotoxic, high potency, biologic, and other sterile injectable drugs. The injectable facility was designed to meet the highest safety levels for manufacturing personnel, as well as to minimize cross contamination, and be compliant with cGMPs for sterile injectable manufacturing.

BioTechnique reports that it will be ready for sterile liquid and lyophilization fill/finish production in 2015.

Source: PSC Investments through Business Wire